We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.
- Authors
Román, Marta; Baraibar, Iosune; López, Inés; Nadal, Ernest; Rolfo, Christian; Vicent, Silvestre; Gil-Bazo, Ignacio
- Abstract
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of patients present advanced disease at onset. However, in the last decade, multiple oncogenic driver alterations have been discovered and each of them represents a potential therapeutic target. Although <italic>KRAS</italic> mutations are the most frequently oncogene aberrations in lung adenocarcinoma patients, effective therapies targeting KRAS have yet to be developed. Moreover, the role of <italic>KRAS</italic> oncogene in NSCLC remains unclear and its predictive and prognostic impact remains controversial. The study of the underlying biology of <italic>KRAS</italic> in NSCLC patients could help to determine potential candidates to evaluate novel targeted agents and combinations that may allow a tailored treatment for these patients. The aim of this review is to update the current knowledge about <italic>KRAS</italic>-mutated lung adenocarcinoma, including a historical overview, the biology of the molecular pathways involved, the clinical relevance of <italic>KRAS</italic> mutations as a prognostic and predictive marker and the potential therapeutic approaches for a personalized treatment of <italic>KRAS</italic>-mutated NSCLC patients.
- Subjects
ONCOGENES; CANCER treatment; NON-small-cell lung carcinoma; TARGETED drug delivery; DRUG development; CANCER prognosis
- Publication
Molecular Cancer, 2018, Vol 17, p1
- ISSN
1476-4598
- Publication type
Article
- DOI
10.1186/s12943-018-0789-x